Our Pipeline
Unique Pathways with Targets That Matter
Teon’s rich pipeline targets unexploited metabolic pathways backed by well-validated science and a track record developing first- and best-in-class GPCR-directed therapies.
Our highly accomplished scientific team methodically develops and evaluates candidates, leveraging decades of expertise in tumor metabolism, cell signaling and GPCR therapeutic design. Our first candidate, TT-702, was developed concept-to-clinic in only 18 months. The momentum continues, solving for unmet needs in cancer care as we advance additional pipeline candidates.
(1) Monotherapy and in combination with KEYTRUDA® (pembrolizumab)
Candidate: TT-816(1)
(Novel Immune Response Modifier)
(1) Monotherapy and in combination with KEYTRUDA® (pembrolizumab)
Candidate: TT-702
Candidate: TT-373
Candidate: TT-X
Our clinical-stage candidates
TT-816
First-in-class small molecule cannabinoid CB2 receptor antagonist acting as a novel immune response modifier being evaluated for the treatment of a broad range of solid tumors including NSCLC, RCC and Ovarian.
TT-702
First-in-class, oral, adenosine A2B receptor antagonist in Phase 1/2 clinical trial for the treatment of patients with a range of difficult-to-treat cancers including mCRPC, TNBC and MSI/MMR.
TNBC = Triple Negative Breast Cancer
MSI = Microsatellite instability
MMR = DNA mismatch repair
RCC = Renal Cell Carcinoma
NSCLC = Non-Small Cell Lung Cancer
Partnerships
In addition to our own internal work, we are pursuing partnerships to help maximize the value of our innovations and advance medicines that make a difference in the lives of patients. We recognize the tremendous need, and value strategic partnerships in moving cancer care forward. To learn more about partnership opportunities, please contact our team.